Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

BioScience Health Innovations (BHIC) EBIAT (2020 - 2026)

BioScience Health Innovations has reported EBIAT over the past 7 years, most recently at -$229907.0 for Q1 2026.

  • Quarterly EBIAT fell 153.87% to -$229907.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$14615.0 through Mar 2026, down 102.58% year-over-year, with the annual reading at $642090.0 for FY2025, 638.03% up from the prior year.
  • EBIAT was -$229907.0 for Q1 2026 at BioScience Health Innovations, up from -$233630.0 in the prior quarter.
  • Over five years, EBIAT peaked at $457704.0 in Q2 2025 and troughed at -$233630.0 in Q4 2025.
  • The 5-year median for EBIAT is -$28917.0 (2022), against an average of $8802.8.
  • The largest YoY upside for EBIAT was 899.53% in 2025 against a maximum downside of 2446.39% in 2025.
  • A 5-year view of EBIAT shows it stood at -$28917.0 in 2022, then crashed by 32.71% to -$38376.0 in 2023, then skyrocketed by 125.95% to $9957.0 in 2024, then plummeted by 2446.39% to -$233630.0 in 2025, then increased by 1.59% to -$229907.0 in 2026.
  • Per Business Quant, the three most recent readings for BHIC's EBIAT are -$229907.0 (Q1 2026), -$233630.0 (Q4 2025), and -$8782.0 (Q3 2025).